DrugPatentWatch Database Preview
FLUOXETINE HYDROCHLORIDE Drug Profile
see a sample report or, see our see our flat-rate plans
When do Fluoxetine Hydrochloride patents expire, and what generic alternatives are available?
Fluoxetine Hydrochloride is a drug marketed by Barr, Dr Reddys Labs Ltd, Alembic Pharms Ltd, Ani Pharms Inc, Aurobindo Pharma, Carlsbad, Cr Double Crane, Heritage Pharms Inc, Ivax Sub Teva Pharms, Landela Pharm, Marksans Pharma, Mylan, Mylan Pharms Inc, Par Pharm, Sandoz, Sciegen Pharms Inc, Specgx Llc, Sun Pharm Inds Ltd, Teva, Teva Pharms Usa, Wockhardt Ltd, Actavis Mid Atlantic, Apotex Inc, Aurobindo Pharma Ltd, Hi Tech Pharma, Lannett Co Inc, Pharm Assoc, Wockhardt Bio Ag, Alvogen, Fosun Pharma, Inventia Hlthcare, Par Form, Par Pharm Inc, and Torrent Pharms Ltd. and is included in forty-eight NDAs.
The generic ingredient in FLUOXETINE HYDROCHLORIDE is fluoxetine hydrochloride. There are twenty-seven drug master file entries for this compound. Seventy-two suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the fluoxetine hydrochloride profile page.
Summary for FLUOXETINE HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 34 |
| NDAs: | 48 |
| Suppliers / Packagers: | 70 |
| Bulk Api Vendors: | 106 |
| Clinical Trials: | 218 |
| Patent Applications: | 3,377 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FLUOXETINE HYDROCHLORIDE |
| DailyMed Link: | FLUOXETINE HYDROCHLORIDE at DailyMed |
Pharmacology for FLUOXETINE HYDROCHLORIDE
| Drug Class | Serotonin Reuptake Inhibitor |
| Mechanism of Action | Serotonin Uptake Inhibitors |
Medical Subject Heading (MeSH) Categories for FLUOXETINE HYDROCHLORIDE
Synonyms for FLUOXETINE HYDROCHLORIDE
| (+-)-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine hydrochloride |
| (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine, hydrochloride |
| (+-)-N-Methyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propylamine hydrochloride |
| (+/-)-FLUOXETINE HYDROCHLORIDE |
| (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine, HCl |
| (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine hydrochloride |
| (S)-N-Methyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine |
| 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine hydrochloride |
| 54910-89-3 (Parent) |
| 56296-78-7 |
| 59333-67-4 |
| 910F893 |
| AB04860 |
| AB2000053 |
| AC-1697 |
| AC1L1XXD |
| Adofen |
| Affectine |
| AK163170 |
| AKOS015894939 |
| Alental |
| Alzac 20 |
| AN-14688 |
| AN-40216 |
| ANW-42507 |
| Apo-Fluoxentine |
| BC208532 |
| BENZENEPROPANAMINE, N-METHYL-G-[4-(TRIFLUOROMETHYL)PHENOXY]-, HYDROCHLORIDE (1:1) |
| Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, hydrochloride |
| Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, hydrochloride, (+-)- |
| Bioxetin |
| C17H18F3NO.HCl |
| CAS-56296-78-7 |
| CCG-39084 |
| CCRIS 6150 |
| CHEMBL1201082 |
| CPD000058452 |
| Cramin |
| CS-1838 |
| CTK8B3427 |
| D00823 |
| Depreks |
| Deproxin |
| Digassim |
| dl-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine, HCl |
| DR001730 |
| DSSTox_CID_635 |
| DSSTox_GSID_20635 |
| DSSTox_RID_75706 |
| DTXSID7020635 |
| EINECS 260-101-2 |
| Equilibrane |
| Erocap |
| EU-0100558 |
| F-132 |
| F0750 |
| Felicium |
| Fluctin |
| Fluctine |
| Fludac |
| Fludeka |
| Flufran |
| Fluneurin |
| Flunil |
| Flunirin |
| Fluox-Puren |
| Fluoxac |
| Fluoxeren |
| Fluoxetin HCl |
| Fluoxetine HCl |
| Fluoxetine (hydrochloride) |
| Fluoxetine Hcl |
| Fluoxetine hydrochloride (JAN/USP) |
| Fluoxetine hydrochloride [USAN:USP] |
| Fluoxetine hydrochloride [USAN] |
| Fluoxetine Hydrochloride 1.0 mg/ml in Methanol (as free base) |
| Fluoxetine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material |
| Fluoxetine hydrochloride, British Pharmacopoeia (BP) Reference Standard |
| Fluoxetine hydrochloride, European Pharmacopoeia (EP) Reference Standard |
| Fluoxetine Hydrochloride, pharmaceutical secondary standard; traceable to USP, PhEur and BP |
| Fluoxetine hydrochloride, solid |
| Fluoxetine hydrochloride, United States Pharmacopeia (USP) Reference Standard |
| Fluoxetine hydrochloride, VETRANAL(TM), analytical standard |
| Fluoxetine hydrochoride |
| Fluoxetine, Hydrochloride |
| Fluoxetine.HCl |
| FluoxetineHydrochloride |
| Fluoxifar |
| Fluoxil |
| Flutin |
| Flutine |
| Fluxen |
| Fluxene |
| Fluxil |
| Fondur |
| Fonzac |
| Foxetin |
| Framex |
| FT-0626490 |
| FT-0652216 |
| GIYXAJPCNFJEHY-UHFFFAOYSA-N |
| HMS1569H03 |
| HMS1922F07 |
| HSDB 6633 |
| HY-B0102A |
| I06-0079 |
| I06-079 |
| IN1336 |
| J-521372 |
| J10277 |
| KM0299 |
| KS-00000JJ6 |
| KS-1061 |
| Lilly 110140 |
| Lorien |
| Lovan |
| LP00558 |
| LS-185085 |
| LS-31041 |
| LS-7403 |
| LY 110140 |
| LY-110,140 hydrochloride |
| LY-110140 |
| LY110140 |
| Margrilan |
| methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine hydrochloride |
| METHYL(3-PHENYL-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)AMINE HYDROCHLORIDE |
| Methyl(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)ammonium chloride |
| METHYL(3-PHENYL-3-[4-(TRIFLUOROMETHYL)PHENOXY]PROPYL)AMINE, CHLORIDE |
| MFCD00214288 |
| Mitilase |
| MLS000069361 |
| MLS001076338 |
| MLS002222264 |
| Modipran |
| MolPort-003-666-535 |
| Motivone |
| Mutan |
| Mutin |
| N-METHYL-3-[(4-TRIFLUOROMETHYL)PHENOXY]-3-PHENYLPROPYLAMINE HYDROCHLORIDE |
| N-methyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine hydrochloride |
| N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) |
| N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propylamine Hydrochloride |
| N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine hydrochloride |
| N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine;hydrochloride |
| N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine Hydrochloride |
| N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine hydrochloride |
| NC00715 |
| NCGC00093943-01 |
| NCGC00093943-02 |
| NCGC00093943-03 |
| NCGC00093943-04 |
| NCGC00093943-05 |
| NCGC00257736-01 |
| NCGC00261243-01 |
| Neupax |
| Nopres |
| NPL-2008 |
| NSC-714457 |
| NSC-758685 |
| NSC714457 |
| NSC758685 |
| Nuzak |
| Nycoflox |
| Opera_ID_1538 |
| OR162195 |
| OR206941 |
| Oxedep |
| Pharmakon1600-01504173 |
| Pragmaten |
| Prestwick_798 |
| Prizma |
| Proctin |
| Prodep |
| Profluzac |
| Propylamine, N-methyl-3-phenyl-3-(p-trifluoromethylphenoxy)-, hydrochloride |
| Prozac |
| Prozac (TN) |
| Prozac 20 |
| Prozac; LY-110,140 hydrochloride |
| Prozac;Sarafem |
| PROZAC(R) HYDROCHLORIDE |
| Psipax |
| Reconcile |
| RL04127 |
| Rowexetina |
| s1333 |
| SAM002589965 |
| Sanzur |
| Sarafem |
| Saurat |
| SBB066066 |
| SC-12129 |
| SC-53387 |
| SCHEMBL33384 |
| Selfemra |
| Seronil |
| Sinzac |
| Siquial |
| SMR000058452 |
| SPECTRUM1504173 |
| SR-01000002988 |
| SR-01000002988-2 |
| ST24047216 |
| Tox21_200182 |
| Tox21_500558 |
| TRA-0205161 |
| TRA0057937 |
| TRA0075235 |
| Tuneluz |
| Verotina |
| Z1741982921 |
| Zactin |
| Zedprex |
| Zepax |
US Patents and Regulatory Information for FLUOXETINE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alvogen | FLUOXETINE HYDROCHLORIDE | fluoxetine hydrochloride | TABLET;ORAL | 202133-001 | Oct 6, 2011 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Sandoz | FLUOXETINE HYDROCHLORIDE | fluoxetine hydrochloride | CAPSULE;ORAL | 077469-001 | Nov 17, 2008 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Mylan | FLUOXETINE HYDROCHLORIDE | fluoxetine hydrochloride | CAPSULE;ORAL | 078045-002 | Nov 17, 2008 | RX | No | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
